Ondine Biomedical (OBI.L) reports H1 2026 operating loss of $15.90 mln
Ondine Biomedical said its H1 2026 operating loss increased to $15.90 million. It also announced the commencement of an equity fund raising process.
Sept 30 (Reuters) — Ondine Biomedical Inc: Ondine Biomedical - 2026 Interim Results & Post-period Momentum Ondine Biomedical H1 Ebit Usd -15.9 Million Ondine Biomedical - H1 2026 Operating Loss Increased To $15.90 Mln Ondine Biomedical - Announces Commencement Of Equity Fund Raising Process Source text:... Further company coverage: OBI.L (Reuters.Briefs@thomsonreuters.com;)